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Effects of oral neomycin and kanamycin in chronic uremic
patients: I. Urea metabolism. The fate of portal ammonia derived
from intestinal urea degradation was examined in 15 experiments
in patients with chronic renal failure. The kinetics of labelled urea
metabolism were studied before and again during the administra-
tion of oral neomycin or kanamycin. Detectable absorption of
both drugs generally occurred, but urea clearance and estimated
glomerular filtration rate did not significantly change during anti-
biotic administration. In seven experiments a significant fall in urea
degradation (65% to 95%) occurred during antibiotic administra-
tion. Analysis of the effect of antibiotics was confined to these
seven experiments. In the control periods, there were no differences
in urea metabolism or renal function between these patients and
those in whom urea degradation was not suppressed. If ammonia
derived from urea degradation is converted back to urea in the
liver, then suppression of degradation would lead to an equal
decrease in urea production, and the difference between produc-
tion and degradation ("appearance") would remain constant.
However, if urea-derived ammonia is used for protein synthesis,
suppression of degradation would permit the formerly degraded
urea to appear in urine and body Iluids and thus to increase
measured urea appearance. In these seven experiments, we found
no change in urea appearance during antibiotic administration. We
conclude that portal ammonia is reincorporated into urea in
chronic renal failure and is not utilized significantly for protein
synthesis.
Effets de In néomycine et de Ia kanamycine administrés par voie
orale a des malades atteints d'urémie chronique: I. Métabotisme de
I'urée. Le devenir de l'ammoniac portal provenant de Ia dégrada-
tion intestinale d'urCe a été étudié chez IS malades atteints
d'insuffisance rénale chronique. Les cinetiques du métabolisme de
l'urée marquee ont été étudiées avant puis pendant
'administration orale de néomycine et de kanamycine. Une ab-
sorption dCcelable de chacune des deux drogues a été observée Ic
plus souvent mais a clearance de l'urée et le debit de filtration
glomCrulaire mesuré n'ont pas été modifies de façon significative
par l'administration de ces antibiotiques. Chez sept des IS malades
Ctudiés une diminution significative de Ia degradation d'urée (65%
C 95%) est survenue pendant Ia prise d'antibiotiques. L'analyse de
l'effet des antibiotiques na Cté réalisCe que chez ces sept malades.
Au cours de Ia periode contróle il ny avait pas de differences dans
Ie métabolisnie de l'urée on Ia fonction rénale entre ces sept mal-
adcs et lcs huit autres. Si I'ammoniac provenant de Ia degradation
de l'urée est a nouveau converti en urée dans Ic foie a suppression
de Ia degradation devrait aboutir C une augmentation Cquivalente
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de Ia production d'urée et Ia difference entre Ia production et Ia
degradation ("apparition") demeurerait constante. Mais si de
l'ammoniac provenant de l'urée est utilisé pour Ia synthese pro-
téique Ia suppression de Ia degradation devrait permettre C l'urée
non dégradCe d'apparaitre dans l'urine ci les liquides corporels et
d'augmenter l'apparition d'urée. Nous n'avons observe aucune
modification de I'apparition d'urée chez ces sept malades au cours
de l'administration d'antihiotiques. Nous concluons que
l'ammoniac portal est converti en urhe au cours de l'insuffisance
rCnale chronique et nest pas utilisé de facon significative pour Ia
synthèse des protéines.
In patients with chronic renal failure, urea reten-
tion results in a large pool of circulating nitrogen (N),
The metabolism of this potential source of nitrogen is
of considerable interest because nitrogen-restricted
diets are commonly employed in. treating patients
with uremia. Urea is degraded by intestinal bacteria
and the resulting ammonia is transported to the liver
[I]. Since urea production exceeds urinary excretion
and since there is no. significant fecal excretion of urea
[2], ammonia from urea degradation may be re-
synthesized into urea. However, portal ammonia may
have other metabolic fates. It is widely believed that
this nitrogen is used in the synthesis of nonessential
amino acids by both normal and uremic patients
[3—6]. It has also been suggested [4, 5] that in uremia,
ammonia derived from urea degradation may pro-
vide a nitrogen source for the amination of keto-
analogues of essential amino acids. Analogues of
some essential amino acids have been shown to sup-
port growth in animals [7] and to maintain nitrogen
balance in normal and uremic man [8—13].
These postulated metabolic consequences of an in-
creased urea nitrogen pool were based on the pre-
sumption that increased serum urea should result in a
greater quantity of urea degraded to ammonia, thus
making more ammonia available for protein syn-
thesis. In support of this hypothesis was the observa-
tion that '5N-labelled ammonia was incorporated
into serum albumin in normal or uremic subjects
during protein restriction [5]. Further study has
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shown, however, that urea degradation is not in-
creased in uremia 114—161. Measurements of urea
metabolism in such patients revealed that the correla-
tion between urea degradation and total urea produc-
tion was positive, implying that ammonia derived
from urea is resynthesized into urea, not in-
corporated into protein [15]. However, Varcoe et al
[16] have recently reported that incorporation of'5N-
ammonia derived from '5N-urea into albumin is 13
times greater in urenlic patients than in normal sub-
jects.
In order to examine this question more directly, we
have reduced urea degradation in patients with
chronic uremia by giving neomycin or kariamyin by
mouth. If portal ammonia from any source is used
for protein synthesis, then antibiotic suppression of
ammonia formation should yield a decrease in net
protein synthesis. Endogenous urea formation (from
sources other than ammonia) might decrease slightly
under these conditions, just as it does when non-
essential nitrogen intake from an external source is
reduced below minimal requirements in normal sub-
jects [17]. This fall in urea production, and therefore
in urea appearance (measured as excretion plus accu-
mulation), is characteristically smaller than the re-
duction in nitrogen intake [17]. In subjects given
antibiotics, however, an internal source of utilizable
nitrogen has been suppressed. The urea nitrogen for-
merly being degraded and utilized would now appear
in urine and body fluids. The net effect would there-
fore be an increase in urea appearance, which is equal
to production minus degradation. On the other hand,
if portal ammonia is converted to urea in the liver,
then a decrease in portal ammonia should lead to an
equivalent decrease in urea production. An equiva-
lent fall in production and degradation would not
change urea appearance.
Methods
Data from 15 experiments in 13 patients (eight men
and five women) with chronic renal failure comprised
this report. In each experiment control observations
of urea kinetics were made in patients receiving either
essential amino acids or a mixture of five keto- and
hydroxy-analogues of essential amino acids and the
four remaining essential amino acids [13]. Control
urea kinetics measured over five to seven days were
compared with similar observations made in the same
subjects while they received oral neomycin or ka-
namycin. Informed written consent was obtained in
all cases for use of keto- and hydroxy-acids, oral
antibiotics, and radioactive urea.
Antibiotics were given in four equally divided oral
doses throughout the day. Plasma levels of both anti-
biotics were measured daily during the week and the
drug was discontinued if an arbitrarily chosen plasma
level of 5 sg/ml of neomycin or 8 tg/ml of kanamy-
cm was detected. These subtherapeutic levels were
chosen to avoid toxicity. Kanamycin and neomycin
were measured by a method developed by one of us
(Dr. Lietman) similar to the method of Haas and
Davies [18]. There was no significant impairment of
renal function during antibiotic administration
(Table I). Initially, a total daily dose of 2 to 4 g of
neomycin or kanamycin was used, but in most cases
urea degradation was not suppressed. In subsequent
experiments, 8 g/day of either drug was used. Two
patients, patient no. 6 and patient no. 7, were studied
twice. On the lower dose of antibiotic, they did not
have decreased urea degradation, but two and three
months later, respectively, suppression of urea degra-
dation occurred on the 8 g/day dose. Thus, there
were seven experiments in which there was a measur-
able response to antibiotics, and eight in which there
was not.
On the basis of these results a clear division ap-
peared between the "responders," each of whom had
a statistically significant decrease in total urea clear-
ance (and, therefore, urea nitrogen degradation), and
the "non-responders," each of whom did not have a
statistically significant decrease in total urea clearance
(Fig. 1).
Studies were performed under metabolic—balance
conditions, the patients being placed on an approxi-
mately constant nitrogen and calorie intake as pre-
viously described [12]. The patients studied in these
experiments were also participating in a long-term,
outpatient program of nutritional therapy for chronic
renal failure which consisted of a protein-restricted
diet with supplements of either essential amino acids
or their nitrogen-free analogues. The exact composi-
tion of these supplements have been described else-
where [13]. Each subject's diet was designed by a
research dietician with an aim to making it acceptable
for long-term outpatient use within these limitations.
The patients had been on the same nutritional regi-
men for two weeks to nine months before the study
was begun. Net dietary nitrogen (nitrogen intake
Table 1. Rena! function measurements (Mean +SEM)
Glomerular
Urea clearance
mi/rn/n
filtration rate
rn//mm
Responders Control 2.66 + 0.66 3.89 + 12!(N = 7) Change —0.15 + 0.13 —0.12 0.13
Non-responders Control 3.23 + 0.61 4.86 1.07(N = 8) Change —0.15 + 0.14 —0.06 0.10
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Fig. I. Lrea degradation rate during antibiotic administration cx—
pressed ax a pers'entage aJ degradation rate he/dre antibiotic adminis—
trot jan in 15 experisnents in 13 patients. In each of the responders,
degradation was significantly reduced.
minus urinary protein nitrogen) averaged 3.92 g/day
in patients receiving essential amino acids, of which
1.14 g was derived from the amino acids, and 3.61
g/day in patients receiving the analogue mixture, 0.39
g of which was derived from the supplement. Essen-
tial amino acids were given in seven experiments (two
showing suppression and five non-suppression) and
the analogue mixture was given in the remaining
eight. Mean caloric intake, including the high carbo-
hydrate supplement, was 32 kilocalories per kg of
body wt. This regimen was adequate to maintain
body weight before, during, and after these studies.
In addition, each patient received 1 mg of folic acid,
50 mg of pyridoxine, and one B vitamin complex
capsule daily. Sufficient sodium bicarbonate to main-
tain serum total-CO2 above 20mM and, if necessary,
aluminum hydroxide were also given.
During each experiment, the dynamics of urea
metabolism were measured on two occasions. 14C-
urea (New England Nuclear Corp., Boston, MA)
was injected after testing for sterility and pyrogenic-
ity, and the plasma concentration of total 14C was
measured approximately every 12 hr for five to seven
days as described previously [IS]. During this period
the urea nitrogen concentration in serum water,
urinary urea nitrogen excretion, and renal clearance
of urea were determined daily. These measurements
and the rate of change of the urea pool [12] permitted
calculation of total urea clearance and its 95% con-
fidence limits, rates of urea degradation and produc-
tion, and the rate of urea nitrogen appearance.
Total urea nitrogen clearance is measured as the
product of the volume of distribution of urea nitro-
gen and the rate of disappearance of injected '4C-urea
[15]. The difference between total urea nitrogen clear-
ance and renal urea nitrogen clearance is designated
as extrarenal urea nitrogen clearance (CM). This value
multiplied by mean plasma urea nitrogen concentra-
tion gives the rate of urea nitrogen degradation (M).
Urea nitrogen appearance (U) is equal to the differ-
ence between urea nitrogen production (A) and urea
nitrogen degradation, M. Urea nitrogen appearance
is measured as the sum of the mean daily urinary urea
nitrogen excretion and mean daily change in body
urea nitrogen pooi.
There was relatively little variation in weight of
these subjects, which may account for the fact that
the coefficients of variation of the measures of urea
metabolism were not reduced when results were ex-
pressed per kg of body weight or per liter of urea
space. Each day, glomerular filtration rate was esti-
mated as the average of 24-hr creatinine and urea
clearances [19].
Urea metabolism observations were made a second
time beginning two or three days after starting oral
antibiotics. Just prior to the second injection of 14C-
urea, a plasma sample was taken and the '4C concen-
tration determined. This value for residual radio-
activity was subtracted from the concentration at
zero time (obtained by extrapolation of the plot of
logarithm of '4C concentration vs. time) and then
used to calculate the confidence limits of total urea
clearance during antibiotics as follows: The uncor-
rected confidence limits were multiplied by the ratio
of the uncorrected intercept value to the uncorrected
intercept minus residual '4C concentration. This
yielded corrected confidence limits for total urea
clearance following the second injection of '4C-urea.
Results
Renal clearances of urea and estimated glomerular
filtration rates for patients in the responder and non-
responder groups are shown in Table I. There were
no significant differences in either measurement be-
tween patients in these two groups, or between
patients receiving essential amino acid supplements
and those receiving the analogue mixture, or between
the groups treated with kanamycin or neomycin.
Observations of urea metabolism during control
and antibiotic administration are presented in Table
2. Serum urea nitrogen concentration (not shown)
can be calculated as M/CM. The measurement of urea
space by injected '4C disappearance (see Methods)
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Table 2. Summary of urea metabolism observations in uremic patients, before and during antibiotic administrations
Patient
no.
Body
wt,
kg
V
liters
CT, liters/day CM, liters/day M, g of N/day A, g of N/day U, g of N/day
Change Control Change Control Change Control Change Control ChangeControl Drug
Responders
1 77.2 45,4 5.09 2.52
(4.60_5.56)b (2.35—2.81 )b
—2.57 3.18 —2.26 2.54 —1.95 4.25 —3.58 2.17 —2.09
2 67.0 34.6 11.18 8.82
(10.74—I l60)b (8.29—9.32)
—2.36 4.59 —2.59 2.94 —2.12 5.51 —2.60 2.57 —0.45
3 67.9 39.4 4.18 1.36
(3.84_4.52)b (l.l3_.l.57)b
—2.82 2.68 —2.32 2.81 —2.47 3.53 —2.39 0.86 —0.06
4 68.2 35.9 7.37 5.24
(7.14—7.60)' (4,37_.5.95)5
—2.13 4.04 —2.70 4.20 —3.19 6.28 —2.87 2.08 +0.32
5 90.6 41.1 7.78 3.75
(7.46_8.ll)b (3.l9_4.3l)l
—4.03 4.46 —3.09 4.42 —3.04 6.72 —2.94 2.30 +0.10
6 86.3 40.5 11.81 8.57
(1 l.44_12.14)b (7.80_9.30)b
—3.24 4.35 —4.15 2.09 —2.01 5.61 —2.40 3.52 —0.39
7 54.0 33.1 5.40 3.30
(4.89—6.05) (2.76—3.78)"
—2.10 3.90 —2.26 3.47 —2.21 4.30 —2.57 0.83 —0.36
Mean 73.0 38.6 7.54 4.79 2.75e 3.88 —2.77" 3.21 —2.43 5.17 —2.76" 2.05 —0.42
+SLM + 4.8 + 1.6 + 1.12 +0.26 +0.26 +0.32 +0.19
Non-responders
(N = 8)
Mean 67.8 35.9 8.05 7.54 —0.51 3.43 —0.28 2.62 +0.05 5.77 —0.10 3.26 —0.11
+ SCM + 5.4 + 2.7 + 0.97 +1.00 +0.32 +0.73 +0.39 +0.47 +0.26 +0.32
a Abbreviations used in this table: V = average of two measurements of volume of distribution of urea; CT = total clearance: C, = extrarenal
clearance; M = degradation rate of urea N; A = production rate of urea N; U = urea N appearance rate.
95% confidence limits.
P < .001.
yields a distribution volume of urea which, when
subtracted from body weight, gives a measure of dry
tissue mass. This estimated value should remain con-
stant during short-term experiments. The estimates
used in this study had a mean change of 8.2 2.2%
(calculated without regard to sign) between the first
and second measurement.
There were no significant differences in control
period measurements of urea metabolism between
the responders and non-responders. Urea degrada-
tion during antibiotic administration did not signifi-
cantly correlate with serum urea concentration. The
95% confidence limits for total clearance are shown,
and as expected [15], were not symmetrical. The aver-
age difference between these limits and the estimates
of total clearance was 10%. In the responders, there
was rio overlap of the lower limit of the control
observation and the upper limit of clearance mea-
sured during the antibiotic period. Thus, total clear-
ance fell significantly in these seven experiments. In
contrast, results of the other eight experiments did
not show a significant change in total urea clearance.
Since renal urea clearance did not change in the
responders (Table 1), the fall in total urea clearance
was entirely attributable to a diminution in extrarenal
clearance, CM, in this group (P < .001). Thus, urea
degradation, M, was significantly decreased in the
responders during oral antibiotic administration (P
< .001). Fig. 1 shows the rate of urea degradation
during antibiotic administration expressed as a per-
centage of the rate before antibiotics in each patient.
Urea degradation decreased 65 to 99% in those re-
sponding but decreased by less than 30% or increased
in those not responding. In the former group there
was a significant (r = 0.89, P < 0.001), though unex-
plained, correlation between the rate of degradation
prior to antibiotics and the decrease in degradation
during antibiotics.
Production of urea, A, was also significantly inhib-
ited during antibiotic administration (P < 0.001) in
the responders. The relationship between urea pro-
duction and urea degradation is plotted in Figure 2.
The lines connect points representing observations
before and during antibiotics in each patient. These
lines demonstrate that the change in production is
nearly equal to the change in degradation in every
case, since they are almost parallel to the line of
identity. Because urea appearance is equal to the
difference between production and degradation of
urea, it follows that urea appearance was unaffected
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by antibiotics. As shown in Table 2, there was indeed
no significant change in urea appearance during anti-
biotic administration in either group. In those re-
sponding, the upper confidence limit (mean + 2 SEM)
of the change in urea nitrogen appearance is +0.18
g/day.
There was also no correlation between urea ap-
pearance and extrarenal clearance in either group (r
= 0.62, P > 0.05; r = 0.45, P > 0.05) as reported
previously [15]. Similarly, there was no correlation
between urea appearance and urea degradation.
The failure of aminoglycoside antibiotics to sup-
press ureolysis in half of these experiments is inter-
esting. There can be no doubt that the drugs were
ingested since detectable concentrations in the blood
were found in all patients receiving kanamycin and in
five of the eight patients receiving neomycin. Specifi-
cally, the mean neomycin concentrations at doses of 8
g/day were 1.17 0.59 sg/ml (three patients) and
1.35 + 0.61 ig/ml (five patients), respectively. Ka-
namycin plasma concentrations at daily doses of 2
and 8 g/day were 3.38 sg/ml (four patients) and 4.67
+ 1.28 sg/m1 (three patients), respectively. In one
patient given 2 g/day kanamycin, a plasma concen-
tration of 15 ig/ml was observed on the fifth morn-
ing of therapy, although it was undetectable on day 2.
The drug was then discontinued and the patient with-
drawn from the study. Two days later, the plasma
concentration had fallen to 9.5 ig/ml. In two other
patients, both on neomycin, the drug dosage was
reduced from 8 to 2 g/day because plasma concentra-
tions of 6 ig/ml and 4 tg/ml were observed. Of the
patients receiving kanamycin, only two were re-
sponders. This apparent difference in efficacy is not
statistically significant by Fisher's exact test.
Discussion
Portal ammonia is derived in part from bacterial
degradation of urea within the gastrointestinal tract
[1, 20] and in part from glutamine taken up by the gut
from arterial blood [2 1-28]. Ammonia formed within
the lumen diffuses into portal blood by non-ionic
diffusion [29]. Bacteria are essential for intestinal
ureolysis since urea concentration in the colon of
germ-free animals [30] or antibiotic-treated man [31]
is similar to the concentration in blood. Furthermore,
labelled urea is not broken down in germ-free rats
[32].
In the early 1960s it was found that patients with
severe renal failure could be maintained in nitrogen
balance despite protein restriction as long as their
diets contained adequate quantities of essential
amino acids [3, 33]. These observations led to the
postulate that ammonia nitrogen derived from urea
breakdown could be used for synthesis of nones-
sential amino acids [3—61. It had been observed earlier
that the nitrogen-free analogues of certain essential
amino acids could be used effectively as substitutes in
animals [7]. This was later confirmed in man [8—13].
These observations provided indirect support for the
hypothesis that ammonia from the circulating urea
pool is important in nitrogen conservation. A corol-
lary to this hypothesis was that increasing concentra-
tions of urea in body fluids would provide greater
amounts of ammonia nitrogen for use by the liver [3,
34, 35]. For example, the extrarenal clearance of
urea, measured in nine normal adults, averaged 22 +
3 liters/day [1, 36]. If extrarenal clearance of urea
were unaltered in uremia, enormous quantities of
ammonia nitrogen would be transported to the liver.
However, urea degradation in patients with uremia
is not increased [14—16]. This is confirmed in the
present study. Combining the present results with
observations of other patients with uremia studied in
this laboratory [15], mean urea degradation is 3.21 +
0.33 g of N/day (N = 30), insignificantly different
from the mean value found in normal subjects (3.3
0.5 g of N/day) [1, 36].
Varcoe et al [16] have recently reported measure-
ments of the incorporation of labelled nitrogen from
urea into serum albumin in normal subjects and in
patients with uremia. Utilization of urea nitrogen,
estimated from these data, was considerably higher in
the uremic patients, but was nevertheless quite small.
As one of the authors of this work has subsequently
pointed out [37], "enrichment of body protein does
not necessarily indicate anything more than an ex-
change of ammonia nitrogen in the hepatic pool."
Therefore, this technique could overestimate urea ni-
trogen reutilization. Furthermore, as Varcoe et al
7
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0 1 2 3 4
Urea N degradation, g/day
Fig. 2. f/rca production and degradation be/bre (circles) and during(squares) antibiotic administration in the seven patients who re-
sponded. Symbols in each patient are joined by lines. The diagonal
line of equality is also shown.
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[16] point out, the only protein they examined was
albumin, and the possibility therefore exists that am-
monia is utilized for synthesis of other hepatic or
extrahepatic proteins. In contrast, the present results
reflect the turnover of all protein and are not ob-
scured by isotopic exchange.
The present results may not apply to individuals in
positive nitrogen balance, i.e., during growth. For
example, Snyderman et al [38] demonstrated more
positive nitrogen balance in children receiving sup-
plemental urea while on low protein diets. Tripathy,
Klahr, and Lotero reported similar results in mal-
nourished adults [39]. These studies are analogous to
numerous earlier experiments in monogastric animals
[40—45], showing that urea can promote growth in
diets consisting predominantly of essential amino
acids.
There are also studies demonstrating that the non-
specific nitrogen requirement in adult men can be met
with urea or ammonium salts [46—50]. In our
patients, non-specific nitrogen requirement was prob-
ably met by the small intake of dietary protein. Thus,
it remains conceivable that urea degradation may
have a small effect in improving nitrogen balance in
uremic patients fed limiting amounts of essential
amino acids as their sole source of nitrogen or in
uremics who are in strongly positive nitrogen bal-
ance.
Could the small residual quantity of urea degraded
during antibiotics have provided nitrogen for protein
synthesis? We believe that it did not for the following
reasons. First, there was no correlation between re-
sidual urea degradation and change in urea nitrogen
appearance. Furthermore, the two patients in whom
urea degradation was most completely suppressed
showed a decline in urea nitrogen appearance. In any
event it is highly improbable that we could not detect
a change in nitrogen metabolism when three-fourths
of the ammonia derived from urea was eliminated.
These experiments appear to invalidate the tradi-
tional concept that urea reutilization is nutritionally
important in uremic patients on nitrogen-restricted
diets and in neutral or negative nitrogen balance.
There must be another mechanism by which certain
patients with uremia maintain nitrogen balance on
nitrogen intakes of less than the normal requirements
[3].
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